GB2495884B - A method of increasing the effect of an activated-potentiated form of an antibody - Google Patents

A method of increasing the effect of an activated-potentiated form of an antibody

Info

Publication number
GB2495884B
GB2495884B GB1302649.7A GB201302649A GB2495884B GB 2495884 B GB2495884 B GB 2495884B GB 201302649 A GB201302649 A GB 201302649A GB 2495884 B GB2495884 B GB 2495884B
Authority
GB
United Kingdom
Prior art keywords
antibody
activated
increasing
effect
potentiated form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1302649.7A
Other languages
English (en)
Other versions
GB201302649D0 (en
GB2495884A (en
Inventor
Iliich Epshtein Oleg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2010129290/15A external-priority patent/RU2525155C2/ru
Priority claimed from RU2010129298/15A external-priority patent/RU2526153C2/ru
Priority claimed from RU2010129291/15A external-priority patent/RU2525156C2/ru
Priority claimed from RU2010129292/15A external-priority patent/RU2523557C2/ru
Priority claimed from RU2010130358/15A external-priority patent/RU2519695C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130355/15A external-priority patent/RU2530638C2/ru
Priority claimed from RU2011110106/15A external-priority patent/RU2523451C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Priority claimed from RU2011127055/15A external-priority patent/RU2536230C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127059/15A external-priority patent/RU2536234C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Individual filed Critical Individual
Publication of GB201302649D0 publication Critical patent/GB201302649D0/en
Publication of GB2495884A publication Critical patent/GB2495884A/en
Publication of GB2495884B publication Critical patent/GB2495884B/en
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
GB1302649.7A 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody Expired - Fee Related GB2495884B (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
RU2010129292/15A RU2523557C2 (ru) 2010-07-15 2010-07-15 Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010129291/15A RU2525156C2 (ru) 2010-07-15 2010-07-15 Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
RU2010129298/15A RU2526153C2 (ru) 2010-07-15 2010-07-15 Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
RU2010129290/15A RU2525155C2 (ru) 2010-07-15 2010-07-15 Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2010130355/15A RU2530638C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2010130358/15A RU2519695C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011110106/15A RU2523451C2 (ru) 2011-03-17 2011-03-17 Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности
RU2011127055/15A RU2536230C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения неврологическо-поведенческих рассторойств развития и способ лечения неврологическо-поведенческих расстройств развития
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
RU2011127059/15A RU2536234C2 (ru) 2011-07-01 2011-07-01 Нейротропное лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody

Publications (3)

Publication Number Publication Date
GB201302649D0 GB201302649D0 (en) 2013-04-03
GB2495884A GB2495884A (en) 2013-04-24
GB2495884B true GB2495884B (en) 2017-05-31

Family

ID=44863151

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1302649.7A Expired - Fee Related GB2495884B (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody

Country Status (25)

Country Link
US (3) US9308275B2 (cg-RX-API-DMAC7.html)
EP (1) EP2593140A2 (cg-RX-API-DMAC7.html)
JP (2) JP2013538186A (cg-RX-API-DMAC7.html)
KR (1) KR20140014059A (cg-RX-API-DMAC7.html)
AR (1) AR082247A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011278038B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013000840A2 (cg-RX-API-DMAC7.html)
CA (1) CA2804966A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2013105A3 (cg-RX-API-DMAC7.html)
DE (1) DE112011102358T5 (cg-RX-API-DMAC7.html)
DK (1) DK201370079A (cg-RX-API-DMAC7.html)
EA (1) EA030566B1 (cg-RX-API-DMAC7.html)
EE (1) EE201300006A (cg-RX-API-DMAC7.html)
ES (1) ES2440393R1 (cg-RX-API-DMAC7.html)
FR (1) FR2962656A1 (cg-RX-API-DMAC7.html)
GB (1) GB2495884B (cg-RX-API-DMAC7.html)
IT (1) ITTO20110639A1 (cg-RX-API-DMAC7.html)
LT (1) LT5988B (cg-RX-API-DMAC7.html)
MX (1) MX2013000543A (cg-RX-API-DMAC7.html)
NO (1) NO20130222A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ606767A (cg-RX-API-DMAC7.html)
PE (1) PE20130398A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500107A1 (cg-RX-API-DMAC7.html)
SG (2) SG187038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012007845A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN103282384A (zh) * 2010-07-15 2013-09-04 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法
EP2595658A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3134718A (en) 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US3901967A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of atropine
SE393532B (sv) 1974-05-02 1977-05-16 Draco Ab Sett att framstella en farmaceutisk zinkberedning for astadkommande av en smaklig, fordragbar, peroral zinklosning innehallande ett zinkkomplex
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
SU1331508A1 (ru) 1985-08-14 1987-08-23 Киевский Кабельный Завод "Укркабель" Устройство дл пневматического массажа урогенитальной сферы человека
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US4987127A (en) 1989-01-31 1991-01-22 Dal Sirany Method of treating a virus outbreak
SU1730144A1 (ru) 1989-02-24 1992-04-30 Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики Способ подавлени репродукции вирусов
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
JP3616091B2 (ja) 1992-10-08 2005-02-02 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
BR9507200A (pt) 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
WO1997009056A1 (fr) 1995-09-07 1997-03-13 L'oreal Extrait d'iridacees et compositions le contenant
CA2251617A1 (en) 1996-02-12 1997-08-14 Oleg Iliich Epshtein Medicament and method of treating an organism with medicaments
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
DE19746868A1 (de) 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2144370C1 (ru) 1999-01-06 2000-01-20 Титиева Наталья Михайловна Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2177795C1 (ru) 2001-02-15 2002-01-10 Эпштей Олег Ильич Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2199345C1 (ru) 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
WO2008007868A1 (en) * 2006-07-13 2008-01-17 Mazence Inc. Composition containing metal-acidic amino acid chelate accelerating absorption of metal
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
JP2008511593A (ja) * 2004-09-03 2008-04-17 セーホーエル．ハンセン アクティーゼルスカブ 受容体リガンドを含む発酵乳又は植物性タンパク質及びその使用
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2008012549A (es) * 2006-04-04 2009-01-14 Dong A Pharm Co Ltd Agente para la prevencion y tratamiento de hiperplasia prostatica que comprende compuesto de pirazolopirimidinona.
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
US20130189707A1 (en) 2010-01-26 2013-07-25 Svetlana Alexandrovna Sergeeva Method of determination of autoantibody level by means of enzyme immunoassay
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
DE112011102356T5 (de) 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit dem Herz-Kreislauf-System in Verbindung stehen
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
MY157564A (en) 2010-07-15 2016-06-30 Epshtein Oleg Lliich Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
CN103282384A (zh) * 2010-07-15 2013-09-04 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法
CN103119061A (zh) * 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
EP2596020A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
GB2496801B (en) * 2010-07-21 2018-04-11 Iliich Epshtein Oleg A method of treating alzheimer's disease
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
EP2595658A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
ES2425315R1 (es) 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
RU2517084C2 (ru) 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
JP2013537532A (ja) 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
US20120263725A1 (en) 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
RU2535034C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2535033C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
US20130171161A1 (en) 2010-12-23 2013-07-04 Oleg Iliich Epshtein Method and composition for the treatment of diseases caused by or associated with hiv
JP5418549B2 (ja) * 2011-07-06 2014-02-19 アイシン精機株式会社 車両のドアアウタハンドル装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. S. ZHAVBERT ET AL: "Evaluation of the efficiency and Safety of Combined Treatment with Impaza and Nitrates in CHD Patients with Erectile Dysfunction", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 148, no. 2, (2009), pages 325-327 *
JONAS WAYNE B ET AL: "A critical overview of homeopathy.", ANNALS OF INTERNAL MEDICINE, AMERICAN COLLEGE OF PHYSICIANS, NEW YORK, NY; US, vol. 138, no. 5, 4 March 2003 (2003-03-04), NEW YORK, NY; US, pages 393 - 399, XP002355318, ISSN: 0003-4819 *
SHANG, A. ; HUWILER-MUNTENER, K. ; NARTEY, L. ; JUNI, P. ; DORIG, S. ; STERNE, J.A. ; PEWSNER, D. ; EGGER, M.: "Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy", THE LANCET, THE LANCET PUBLISHING GROUP, GB, vol. 366, no. 9487, 27 August 2005 (2005-08-27), GB, pages 726 - 732, XP025277623, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(05)67177-2 *
VICKERS A J: "CLINICAL TRIALS OF hOMEOPATHY AND PLACEBO: ANALYSIS OF A SCIENTIFIC DEBATE", JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, vol. 6, no. 1, (2000), pages 49-56 *

Also Published As

Publication number Publication date
JP2013538186A (ja) 2013-10-10
MX2013000543A (es) 2013-10-28
LT5988B (lt) 2014-01-27
DK201370079A (en) 2013-02-14
EP2593140A2 (en) 2013-05-22
CA2804966A1 (en) 2012-01-19
ES2440393R1 (es) 2014-10-10
AR082247A1 (es) 2012-11-21
EA030566B1 (ru) 2018-08-31
BR112013000840A2 (pt) 2016-06-07
NO20130222A1 (no) 2013-03-22
GB201302649D0 (en) 2013-04-03
AU2011278038A1 (en) 2013-03-07
US9308275B2 (en) 2016-04-12
SG187038A1 (en) 2013-02-28
US20140079696A1 (en) 2014-03-20
WO2012007845A2 (en) 2012-01-19
SG10201505561TA (en) 2015-08-28
PH12013500107A1 (en) 2013-03-11
DE112011102358T5 (de) 2013-04-25
WO2012007845A3 (en) 2012-03-29
PE20130398A1 (es) 2013-04-10
JP2016216483A (ja) 2016-12-22
FR2962656A1 (fr) 2012-01-20
NZ606767A (en) 2015-08-28
US20160251448A1 (en) 2016-09-01
ES2440393A2 (es) 2014-01-28
US20160244531A1 (en) 2016-08-25
EA201300126A1 (ru) 2013-12-30
CZ2013105A3 (cs) 2013-05-22
LT2013016A (lt) 2013-11-25
GB2495884A (en) 2013-04-24
AU2011278038B2 (en) 2017-02-02
EE201300006A (et) 2013-08-15
ITTO20110639A1 (it) 2012-01-16
KR20140014059A (ko) 2014-02-05

Similar Documents

Publication Publication Date Title
IL259826A (en) Anti-alphabetatisiar antibody
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
PL2581113T3 (pl) Przeciwciało anty-tim-3
PL3342786T3 (pl) Przeciwciało przeciwko dll3
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201307983B (en) Anti-b7-h3 antibody
IL221371A0 (en) Anti-lrp6 antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
GB201106478D0 (en) Immunoassay
PT2603528T (pt) Anticorpos glicosilados em fab
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
TWI563004B (en) Anti-hxcr1 antibody
GB2495884B (en) A method of increasing the effect of an activated-potentiated form of an antibody
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201007957D0 (en) Antibody
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies
GB201017780D0 (en) Antibody

Legal Events

Date Code Title Description
R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20160311

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20160406

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20160421

Free format text: EXTENSION APPLICATION

Effective date: 20160419

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20160620

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20160620

Free format text: EXTENSION ALLOWED

Effective date: 20160914

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20170316

Free format text: EXTENSION APPLICATION

Effective date: 20170116

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20180715